Login / Signup

Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors.

Jessica A WalshIris LinRuizhi ZhaoNatalie J ShiffLaura MorrisonBruno EmondLouise H YuSamuel SchwartzbeinPatrick LefebvreDominic PilonSoumya D ChakravartyPhilip Mease
Published in: Drugs - real world outcomes (2024)
This real-world study employing US commercial health-plan claims data to assess on-label treatment persistence in PsA demonstrated that, at 12 months, guselkumab was associated with a 3 times greater likelihood of persistence compared with SC TNFi.
Keyphrases
  • prostate cancer
  • healthcare
  • public health
  • combination therapy
  • risk assessment
  • deep learning
  • smoking cessation
  • human health